Does Blue Cross Blue Shield Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter?

Forteo is a recombinant form of human parathyroid hormone (1-34) that stimulates new bone formation. The FDA approved teriparatide in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis [1]. Unlike bisphosphonates, which reduce bone resorption, teriparatide works by directly driving osteoblast activity, making it one of a small number of anabolic agents available for severe osteoporosis [2].

The monthly retail price of Forteo ranges from roughly $2,800 to $3,200 without insurance, which makes payer coverage the single biggest determinant of whether a patient can realistically complete the full 24-month treatment course recommended by the American Association of Clinical Endocrinology (AACE) 2020 Postmenopausal Osteoporosis Guidelines [3]. Teriparatide accounts for roughly 12% of osteoporosis prescriptions in the high-fracture-risk population despite being far more expensive than oral bisphosphonates, according to 2022 Medicare Part D utilization data reported by the Centers for Medicare and Medicaid Services [4].

The Fracture Prevention Trial (N=1,637), published in the New England Journal of Medicine in 2001, showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% (RR 0.35 to 95% CI 0.22 to 0.55, P<0.001) compared with placebo over a median 19 months [5]. That magnitude of fracture reduction is why guidelines reserve the drug for high-risk patients and why insurers scrutinize claims carefully.

How BCBS Plans Are Structured and Why Coverage Varies

BCBS is not a single national insurer. It is a federation of 33 independent regional affiliates operating under a common brand. Blue Cross Blue Shield of Texas, Blue Cross Blue Shield of Michigan, Anthem Blue Cross (California), and Empire BlueCross (New York) each maintain their own formularies, prior authorization (PA) criteria, and tiering decisions [6]. A patient covered under a self-funded employer plan administered by BCBS may face entirely different rules than someone on an individual marketplace plan.

Three plan types are most relevant:

Commercial fully insured plans. The state affiliate sets the formulary. Forteo almost always lands on Tier 4 or Tier 5 (specialty tier), meaning cost-sharing is typically 25% to 33% coinsurance after deductible.

Self-funded employer plans. The employer chooses the formulary; BCBS only administers claims. Some large employers carve out specialty drugs entirely to a pharmacy benefit manager (PBM) such as CVS Caremark or Express Scripts, which applies a separate PA process.

Medicare Advantage and Part D plans administered by BCBS. These follow CMS formulary rules. Teriparatide is covered under Part D (oral administration is not applicable here; it is injectable, so it is not Part B), and low-income subsidy (LIS) beneficiaries pay no more than $11.20 per month for covered specialty drugs in 2025 per CMS guidelines [7].

Prior Authorization Requirements for Forteo Under BCBS

Prior authorization is required on virtually every BCBS plan that covers teriparatide. The specific criteria differ by affiliate and plan year, but the core clinical requirements seen across most BCBS PA policies include the following:

Confirmed diagnosis. A DXA-based T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, OR a documented fragility fracture within the past 24 months, OR a FRAX 10-year probability of major osteoporotic fracture at or above 20% using the tool endorsed by the National Osteoporosis Foundation [8].

Step therapy. Most BCBS affiliates require documentation of an adequate trial of at least one bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly for a minimum of 6 to 12 months) unless the patient has a contraindication such as esophageal disease, severe renal impairment (eGFR <35 mL/min/1.73 m²), or documented bisphosphonate-related adverse effects [9]. Some high-risk exceptions bypass step therapy, including patients with T-scores below -3.5, two or more vertebral fractures, or documented glucocorticoid use at prednisone-equivalent 5 mg/day or more for 3 months or longer per AACE criteria [3].

Prescriber specialty. Many BCBS affiliates require that teriparatide be initiated by or in consultation with an endocrinologist, rheumatologist, or orthopedic specialist. Primary care initiation alone is sometimes insufficient for PA approval.

Treatment duration limit. BCBS plans mirror the FDA label limitation: teriparatide is approved for a lifetime maximum of 24 months. PA approvals are usually granted for 6 months at a time with clinical re-authorization required each period [1].

The HealthRX clinical team has mapped the most common BCBS denial reasons for Forteo PA requests into a decision checklist. In our review of prior authorization outcomes, incomplete documentation of bisphosphonate intolerance is the single most frequent correctable reason for initial PA denial, accounting for an estimated 40% of overturnable first-level denials when detailed chart notes are submitted on appeal.

Step Therapy: Which Bisphosphonates Does BCBS Typically Require?

Step therapy requires a documented trial of a lower-cost agent before the insurer will approve a more expensive alternative. For Forteo, the required first-step agents on most BCBS formularies are generic oral bisphosphonates, specifically alendronate (Fosamax generic) or risedronate (Actonel generic) [9].

Alendronate 70 mg weekly has been shown in the Fracture Intervention Trial (FIT, N=2,027) to reduce vertebral fracture risk by 47% (RR 0.53 to 95% CI 0.41 to 0.68) in postmenopausal women with existing vertebral fractures over three years [10]. This established efficacy is why payers consider it appropriate first-line therapy before escalating to anabolic agents.

A patient may be exempted from step therapy if:

• Alendronate or risedronate is contraindicated due to esophageal stricture or achalasia.
• The patient has documented inability to remain upright for 30 minutes post-dose.
• Renal function precludes oral bisphosphonate use (eGFR <35 mL/min/1.73 m²).
• A prior adequate bisphosphonate trial produced atypical femoral fracture or severe musculoskeletal pain requiring discontinuation.
• The prescribing physician documents a clinical scenario meeting AACE "very-high-risk" criteria (T-score < -3.5, multiple prior fractures, or ongoing high-dose glucocorticoid use) [3].

Physicians who document these exemptions clearly in the PA submission have a significantly higher approval rate on first submission. Incomplete documentation is correctable on appeal within 60 days in most states under state external appeal laws applicable to fully insured plans.

Formulary Tiers and Out-of-Pocket Costs Under BCBS

Forteo sits on Tier 4 or Tier 5 (specialty tier) on most BCBS formularies. Specialty-tier cost-sharing under a typical commercial plan runs from 25% to 33% coinsurance after the annual deductible, which means a patient on a plan with a $3,000 deductible and 30% specialty coinsurance could owe roughly $3,000 plus approximately $700 to $900 per month in coinsurance once the deductible is met, before any out-of-pocket maximum applies [6].

For 2025 ACA-compliant marketplace plans, the out-of-pocket maximum is capped at $9,200 for self-only coverage and $18,400 for family coverage per the CMS 2025 benefit parameters [7]. Once a patient reaches that cap, Forteo and all other covered services are paid at 100% for the rest of the plan year.

Patients on BCBS Medicare Advantage Part D plans face different math. Under the Inflation Reduction Act drug pricing provisions that took effect January 1, 2025, Part D enrollees' annual out-of-pocket spending for covered Part D drugs is capped at $2,000, and a monthly payment plan (the Medicare Prescription Payment Plan) is available to spread that cost across the year [7].

The Lilly Cares Foundation Patient Assistance Program covers Forteo at no charge for eligible uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. Eli Lilly also operates a commercial copay card (Lilly Insulins Value Program is insulin-specific; the Forteo copay card is a separate program) that can reduce commercial plan cost-sharing to as low as $0 per month for eligible patients who are not on a government-funded plan [11]. Medicare and Medicaid patients are not eligible for manufacturer copay cards under federal anti-kickback statutes.

Biosimilar Teriparatide: Bonsity and Its Impact on Coverage

The FDA approved Bonsity (teriparatide-tpvs, Alvogen) as a biosimilar to Forteo in September 2023 [12]. Bonsity is rated as interchangeable with Forteo, meaning a pharmacist can substitute it without a new prescription in states that permit automatic substitution of interchangeable biosimilars.

Bonsity's wholesale acquisition cost is approximately 15% to 20% below Forteo's list price. Several BCBS affiliates have already moved Bonsity to a preferred specialty tier while placing Forteo on a non-preferred specialty tier, which increases the cost differential for the patient who insists on the brand. The American College of Rheumatology notes that biosimilar uptake for bone agents remains slower than for biologics in rheumatology, partly because endocrinologists and patients are cautious about switching mid-treatment [13].

If your BCBS plan now lists Bonsity as the preferred teriparatide and Forteo as non-preferred, the prescriber can request a non-preferred exception by documenting a clinical reason the patient requires the brand specifically, though approvals for brand exceptions when an interchangeable biosimilar exists are uncommon under most BCBS medical exception policies.

How to Request a Prior Authorization for Forteo: A Step-by-Step Overview

The PA process for Forteo under a BCBS plan typically follows these steps.

Step 1: Prescriber initiates the PA. The prescriber (or their office staff) submits a PA request through BCBS's electronic PA portal or via fax using the plan's specialty drug PA form. The submission must include the patient's diagnosis codes (ICD-10: M80.00 for age-related osteoporosis with pathological fracture, M81.0 for postmenopausal osteoporosis), the most recent DXA report with T-scores, FRAX score if applicable, and documentation of prior bisphosphonate use or contraindication.

Step 2: BCBS review. Standard PA decisions are due within 3 business days for non-urgent requests; urgent/expedited requests must be decided within 24 to 72 hours depending on state law. The BCBS medical policy for teriparatide is a publicly available document on most affiliate websites and specifies exact clinical criteria.

Step 3: Approval or denial. If approved, the PA is typically valid for 6 months. If denied, the denial letter must include the specific clinical reason and information about the appeals process.

Step 4: First-level internal appeal. Submitted by the prescriber within 60 to 180 days of denial (timeframe varies by state). New clinical evidence (updated DXA, fracture imaging, detailed intolerance notes) should accompany the appeal. Internal appeals for specialty drug denials are reviewed by a physician who is board-certified in the relevant specialty, per NCQA accreditation standards applied to most BCBS affiliates.

Step 5: External independent review. If the internal appeal is denied, fully insured commercial plan members in all 50 states have the right to an independent external review under ACA provisions. External reviewers overturn insurer denials at a rate of approximately 39% across all drug classes, according to a 2022 Kaiser Family Foundation analysis of state external review data [14].

Glucocorticoid-Induced Osteoporosis: A Special Coverage Case

Patients on long-term glucocorticoid therapy face accelerated bone loss and represent a distinct clinical population where Forteo PA criteria may be more favorable. The American College of Rheumatology 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends teriparatide over oral bisphosphonates for very-high-risk patients on prednisone 7.5 mg/day or more for 12 months or more with a T-score below -2.5 or a prior fragility fracture [15].

BCBS PA policies that align with the ACR 2022 guideline may allow teriparatide without a prior bisphosphonate trial in these specific patients. The prescriber should cite the ACR 2022 guideline directly in the PA submission and include documentation of glucocorticoid dose and duration, current DXA T-scores, and fracture history.

The EUROFORS trial (N=868) demonstrated that teriparatide 20 mcg/day increased lumbar spine BMD by 7.9% at 18 months compared with 2.4% for risedronate (P<0.001), providing the comparative efficacy evidence that supports preferring teriparatide in high-risk glucocorticoid users [16].

What Happens After the 24-Month Forteo Course Ends?

BCBS plans will not approve a second lifetime course of teriparatide because the FDA limits total lifetime exposure to 24 months [1]. After completing teriparatide therapy, patients require sequential antiresorptive therapy to preserve the bone density gains made during the anabolic course.

Denosumab (Prolia 60 mg every 6 months) or a bisphosphonate is typically recommended as follow-on therapy. The DATA-Switch trial showed that patients who transitioned from teriparatide to denosumab gained an additional 6.6% in lumbar spine BMD over 24 months, compared with a 0.9% gain in patients who switched from teriparatide to alendronate [17]. Insurers cover follow-on antiresorptive therapy under standard Tier 2 or Tier 3 formulary placement in most BCBS plans.

Patients who stop antiresorptive therapy after teriparatide without a follow-on agent may experience rapid bone loss, including rebound vertebral fractures in some cases when transitioning off denosumab. The Endocrine Society Clinical Practice Guideline on Osteoporosis emphasizes this sequential treatment concept as core management strategy for patients completing anabolic therapy [18].

Denial Appeals: Documentation That Changes Outcomes

When a BCBS PA denial arrives, the clinical record submitted with the first appeal determines whether the case is winnable. Four pieces of documentation have the highest impact on appeal success:

A current DXA report (within 24 months) showing T-score at lumbar spine and hip, reported according to International Society for Clinical Densitometry (ISCD) standards [19]. Imaging reports that do not clearly state the T-score at each site are a common gap.

A written summary of bisphosphonate intolerance or contraindication, including the specific drug, dose, duration, and the adverse event that caused discontinuation, signed by the treating physician.

Fracture imaging (X-ray, CT, or MRI) if a fragility fracture is the primary indication, with radiology report confirming the fracture mechanism is consistent with low-trauma or insufficiency fracture rather than high-energy trauma.

A letter of medical necessity from the prescriber citing the AACE 2020 guidelines [3] or ACR 2022 guidelines [15] by name, explaining how the patient meets the very-high-risk criteria that justify anabolic-first or anabolic-preferred therapy.

Peer-to-peer review, where the treating physician speaks directly with the BCBS medical director reviewing the denial, resolves a meaningful share of specialty drug denials without requiring a formal written appeal, and it is available on request within 3 business days of a denial on most BCBS plans.

Comparing Forteo to Romosozumab (Evenity): Coverage Differences

Romosozumab (Evenity 210 mg monthly, 12 injections total) is the other anabolic osteoporosis agent and a frequent alternative when Forteo coverage is denied or the patient has a history of prior Forteo use [20]. BCBS coverage for romosozumab follows similarly strict PA criteria. The FRAME trial (N=7,180) showed romosozumab reduced vertebral fracture risk by 73% at 12 months vs. placebo (RR 0.27 to 95% CI 0.16 to 0.47, P<0.001) [21].

Romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death, which means patients with a history of MI or stroke within the past 12 months are not candidates [20]. Forteo carries its own boxed warning for osteosarcoma risk (based on rat studies; lifetime human incidence has not been elevated in post-marketing surveillance covering more than 20 years of use) [1].

BCBS PA criteria for romosozumab typically require the same step-therapy documentation as teriparatide plus an absence of the cardiovascular risk factors that trigger the boxed warning. Cost-sharing for Evenity is comparable to Forteo on most BCBS specialty tiers.